Saturday 17 October 2026 Export ANGO’s income statement to Excel — free account

AngioDynamics, Inc.

ANGO Healthcare Medical Instruments & Supplies

AngioDynamics, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $320.2 million, up 9.46% from fiscal 2025. In the quarter to August 2026, revenue grew 6.87%, EPS grew 35.0% and free cash flow grew 5.62%, each against the same quarter a year earlier.

11.25 0.33 −2.85%

Follow ANGO

Alert me

Market cap: $487.0M
P/E: 0.0×
Fwd P/E: −20.7×
Dividend yield: —
F-score: 5/9
Altman Z: 1.63
Beneish M: −3.08
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.34

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	1	—	—	—

Insider Ownership 11.45%

Capital & Financial Ratios $m

Market Cap 486.99

Revenue 325.38

Net Income (32.94)

Free Cash Flow 1.44

Net Debt (33.97)

Current Ratio 2.40

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (20.70)

P/S ratio 1.45

P/B ratio 2.88

Past 5Y EPS Growth —

This Y EPS Growth (85.80%)

Next Y EPS Growth 59.34%

Next Y revenue growth 5.47%

Next 5Y EPS Growth 41.52%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 32.25%

10-year low 10-year high

P/B against its own 10 years 95.76%

10-year low 10-year high

EV/Sales against its own 10 years 31.81%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	76	56	54	34
Receivables	44	43	48	45
Inventory	61	62	52	55
Other	—	—	—	—
	193	168	163	143

	2024	2025	2026	Q'26
Payables	38	33	32	27
ST’ Debt	—	—	—	—
Other	12	7	4	4
	91	76	75	60

Compound Annual Growth %

	10y	5y	3y
Sales	(1.00%)	1.93%	(1.86%)
Cash Flow	(23.54%)	(33.69%)	240.86%
Earnings	0.00%	0.00%	0.00%
Book Value	(10.31%)	(17.22%)	(23.28%)

Revenue $m

	Aug	Nov	Feb	May	Year
’26	81	—	—	—	—
’26	76	79	78	87	320
’25	67	73	72	80	292
’24	79	79	75	71	304
’23	82	85	81	91	339
’22	77	78	74	87	316
’21	70	73	71	77	291

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	(15)	—	—	—	—
’26	(16)	5	(3)	17	3
’25	(18)	2	(13)	19	(10)
’24	(26)	5	(13)	5	(28)
’23	(25)	7	1	16	0
’22	(9)	2	(9)	9	(7)
’21	(5)	11	6	12	24

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	(16)	—	—	—	—
’26	(17)	4	(4)	17	1
’25	(19)	2	(15)	18	(15)
’24	73	5	18	4	101
’23	(26)	6	0	15	(4)
’22	(10)	1	(10)	8	(11)
’21	(7)	10	4	12	19

Fiscal quarters ending in the months shown.

EPS $

	Aug	Nov	Feb	May	Year
’26	(0.17)	—	—	—	—
’26	(0.26)	(0.15)	(0.19)	(0.27)	(0.88)
’25	(0.31)	(0.26)	(0.11)	(0.15)	(0.83)
’24	1.15	(0.72)	(4.73)	(0.33)	(4.59)
’23	(0.33)	(0.21)	(0.24)	(0.54)	(1.33)
’22	(0.18)	(0.21)	(0.13)	(0.16)	(0.68)
’21	(0.11)	(0.11)	(0.09)	(0.51)	(0.82)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	14.80	15.16	13.72	7.48	14.96	11.71	6.01	5.26	8.27	9.39	Analyst estimates 2027–2029 Powerpack
	High	18.85	24.49	25.48	17.24	32.00	30.00	15.96	9.58	13.99	16.29
People
People	Employees	1,250	1,145	1,050	800	800	760	815	748	675	632
	Revenue/emp, $m	0.22	0.23	0.26	0.33	0.36	0.42	0.42	0.41	0.43	0.51
Income, $m
Income, $m	Revenue	270	262	271	264	291	316	339	304	292	320
	Gross margin, %	53.36	54.98	57.64	56.89	53.88	52.41	51.44	50.90	53.92	54.62
	EBT	(14)	(17)	(15)	(168)	(36)	(30)	(54)	(192)	(34)	(36)
	EBT margin, %	(5.30)	(6.60)	(5.43)	(63.65)	(12.39)	(9.47)	(16.07)	(63.06)	(11.63)	(11.34)
	Net income	5	16	61	(167)	(32)	(27)	(52)	(184)	(34)	(37)
	Depreciation	25	23	26	182	26	29	45	187	26	23
Per share, $
Per share, $	Revenue	7.37	7.06	7.22	6.96	7.59	8.11	8.58	7.56	7.16	7.71
	Earnings	0.19	0.44	1.64	(4.37)	(0.82)	(0.68)	(1.33)	(4.59)	(0.83)	(0.88)
	Cash flow	1.52	1.11	1.00	(0.38)	0.63	(0.18)	0.00	(0.70)	(0.25)	0.07
	Capex	(0.08)	(0.10)	(0.08)	(0.20)	(0.14)	(0.11)	(0.11)	3.20	(0.11)	(0.06)
	Free cash flow	1.44	1.02	0.92	(0.58)	0.49	(0.29)	(0.11)	2.50	(0.36)	0.01
	Book value	14.07	14.64	16.40	11.98	11.46	10.88	9.58	5.12	4.48	4.11
	Shares, m	37	37	37	38	38	39	39	40	41	42
Valuation, ×
Valuation, ×	P/E	79.37	47.17	11.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2.05	2.98	2.60	1.49	3.09	2.42	1.10	0.83	1.35	1.42
	P/B	1.07	1.44	1.15	0.87	2.05	1.80	0.99	1.23	2.17	2.65
	EV/Sales	2.22	3.04	2.25	1.47	3.02	2.43	1.14	0.77	1.35	1.42
	EV/FCF	12.46	23.16	20.43	(17.48)	47.42	(64.98)	(80.22)	2.35	(21.50)	(138.33)
Cash, $m
Cash, $m	Operating cash flow	56	41	37	(15)	24	(7)	0	(28)	(10)	3
	Capex	(3)	(4)	(3)	(8)	(5)	(4)	(4)	129	(4)	(3)
	Free cash flow	53	38	34	(22)	19	(11)	(4)	101	(15)	1
Balance, $m
Balance, $m	Working capital	82	111	242	101	83	69	80	102	92	89
	Total debt	96	92	132	40	20	25	50	—	—	—
	Net debt	48	16	(96)	(14)	(28)	(4)	5	(76)	(56)	(54)
	Shareholders’ equity	515	543	615	455	439	424	378	206	183	171
Returns, %
Returns, %	ROA	0.70	2.31	7.96	(23.32)	(5.46)	(4.77)	(9.66)	(43.36)	(11.37)	(13.43)
	ROIC	(1.24)	(1.58)	(1.13)	(23.71)	(5.36)	(4.23)	(8.34)	(92.85)	(19.65)	(21.34)
	ROE	0.98	3.09	10.60	(31.18)	(7.06)	(6.15)	(13.07)	(63.15)	(17.50)	(20.77)

Negative figures in brackets.

All 10 years →

Fiscal years to May 2026 · latest quarter Aug 2026 · fundamentals updated 13 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
STAA STAAR Surgical Company	$1.1B	304×	103×	+111.04% (above 0%: growing)	n/m	+166.10% (above 0%: growing)	74.55%	10.80%	Compare
AVR Anteris Technologies Global Corp.	$619.8M	— (loss-making)	—	+63.27% (above 0%: growing)	n/m	−6.84% (below 0%: shrinking)	76.91%	(3,072.05%)	Compare
ANGO AngioDynamics, Inc.	$487.0M	— (loss-making)	— (loss-making)	+6.87% (above 0%: growing)	n/m	+5.62% (above 0%: growing)	59.37%	(9.02%)
NNNN Anbio Biotechnology	$474.8M	—	—	—	—	—	—	—	Compare
EMBC Embecta Corp.	$365.5M	4.2×	3.8×	−8.05% (below 0%: shrinking)	−53.85% (below 0%: shrinking)	−49.63% (below 0%: shrinking)	56.42%	17.92%	Compare
ZJYL Jin Medical International Ltd.	$340.9M	—	—	—	—	−8,074.17% (below 0%: shrinking)	34.44%	0.00%	Compare
SMTI Sanara MedTech Inc.	$322.4M	— (loss-making)	125×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%	Compare
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
Median of peers	$353.2M	22.7×	65.9×	+3.56%	—	−6.84%	56.42%	10.80%

All 55 Medical Instruments & Supplies stocks →

AngioDynamics, Inc. (ANGO) key facts

Strength: AngioDynamics, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $320.2 million, up 9.46% from fiscal 2025.
AngioDynamics, Inc. (ANGO) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ANGO traded at $11.25, a market capitalization of $487.0 million.
Return on equity was −20.8% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.63 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 13, 2026.